Compare CACI & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | LNTH |
|---|---|---|
| Founded | 1962 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 6.6B |
| IPO Year | 2007 | 2014 |
| Metric | CACI | LNTH |
|---|---|---|
| Price | $621.64 | $100.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $689.50 | $87.00 |
| AVG Volume (30 Days) | 228.5K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.24 | N/A |
| EPS | ★ 24.16 | 2.91 |
| Revenue | ★ $4,467,860,000.00 | $343,374,000.00 |
| Revenue This Year | $12.42 | N/A |
| Revenue Next Year | $10.00 | $14.19 |
| P/E Ratio | ★ $25.12 | $34.60 |
| Revenue Growth | 2.60 | ★ 3.62 |
| 52 Week Low | $434.70 | $49.67 |
| 52 Week High | $683.50 | $111.86 |
| Indicator | CACI | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 54.84 | 45.34 |
| Support Level | $599.30 | $100.51 |
| Resistance Level | $632.80 | $101.43 |
| Average True Range (ATR) | 16.99 | 0.52 |
| MACD | -7.21 | 0.10 |
| Stochastic Oscillator | 42.56 | 38.70 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.